Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403188 · ClinicalTrials.gov registry record
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
A clinical trial of Multiple Sclerosis and Dermatomyositis, sponsored by Kyverna Therapeutics.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT07403188 is a study of Multiple Sclerosis and Dermatomyositis that is actively recruiting participants, run by Kyverna Therapeutics. The registered enrollment target is 70 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07403188, a study of Multiple Sclerosis and Dermatomyositis, is actively recruiting participants, sponsored by Kyverna Therapeutics.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Conditions Studied
Interventions
- DRUG KYV-101
Study Locations (1)
Colorado
- University of Colorado, Denver - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2041-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07403188
The ClinicalTrials.gov registry entry for NCT07403188 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower). The listed sponsor is Kyverna Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which KYV-101 is the first listed.
NCT07403188 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT07403188 about?
NCT07403188 is a clinical study titled "A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101". The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product)....
What is the current status of trial NCT07403188?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2025-11-24. Estimated completion is 2041-01.
What conditions does trial NCT07403188 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Dermatomyositis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Myasthaenia Gravis.
What interventions are being tested in trial NCT07403188?
The interventions under investigation include: KYV-101 (DRUG).
Who is sponsoring clinical trial NCT07403188?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07403188 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.